Skip to main content

Table 1 patient’s characteristics

From: Can clinical and urodynamic parameters predict the occurrence of neutralizing antibodies in therapy failure of intradetrusor onabotulinumtoxin A injections in patients with spinal cord injury?

Patient’s characteristics

 

No. pts.

414

No. pts. with Non-Response

69

male (%)

53 (77)

female (%)

16 (23)

Tetraplegic n (%)

24 (35)

Paraplegic n (%)

45 (65)

AIS A n (%)

49 (71)

AIS B n (%)

9 (13)

AIS C n (%)

7 (10)

AIS D n (%)

4 (6)

C1 – C4, AIS A, B, C n (%)

8 (12)

C5– C8, AIS A, B, C n (%)

13 (19)

T1 – S5, AIS A, B, C n (%)

44 (64)

any level, AIS D n (%)

4 (5)

Age at SCI/D (mean; SD; range), years

31.76; 13.99; 4–73

Age at first BoNT-A injection (mean; SD; range), years

39.56; 14.33; 14–85

  1. (NR Non response, AIS American Spinal Injury Association Impairment Scale, SCI/D Spinal cord injury/disease, BoNT-A botulinum neurotoxin A)